Loading...
 

Volume 32, Issue 3, September 2021




Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2021;32(3):218-26
Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases
Authors Information

1. Department of Rheumatology, "Asklepieion" General Hospital, Athens, Greece

2. Department of Rheumatology, Agios Andreas Hospital, Patras, Greece

3. Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece

4. Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece

References
  1. Farhood B, Najafi M, Mortezaee K. CD8 + cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol 2019 Jun;234(6):8509-21.
  2. Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 2018 Jan;29(1):71-83.
  3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015 Apr;348(6230):56-61.
  4. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378(2):158-68.
  5. Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken) 2017 Nov;69(11):1751-63.
  6. Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Vol. 14, Nature Reviews Rheumatology. Nature Publishing Group; 2018. p. 569-79.
  7. Tocut M, Brenner R, Zandman-Goddard G. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev [Internet] 2018;17(6):610-6.
  8. Melissaropoulos K, Klavdianou K, Filippopoulou A, Kalofonou F, Kalofonos H, Daoussis D. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. Int J Mol Sci 2020 May 11;21(9):3389.
  9. Angelopoulou F, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatol Int 2021 Jan;41(1):33-42.
  10. Daoussis D, Kraniotis P, Filippopoulou A, Argiriadi R, Theodoraki S, Makatsoris T, et al. An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding. Rheumatol (United Kingdom) 2020 May;59(5):1041-50.
  11. Kostine M, Finckh A, Bingham CO 3rd, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2020 Apr 2021;80:36-48.
  12. Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2011 Dec;84(11):1245-52.
  13. Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition. N Engl J Med 2005 Sep;353(11):1114-23.
  14. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. JAMA Oncol 2016;2(2):234-40.
  15. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and pre-existing autoimmune disorders or major toxicity with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol 2017 Feb;28(2):368-76.
  16. Ohnuma K, Hatano R, Dang NH, Morimoto C. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Mod Rheumatol 2019 Sep;29(5):721-32.
  17. Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos F-X, Routier E, et al. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Pre-existing Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol (Hoboken, NJ) 2019 Dec;71(12):2100-11.
  18. Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, et al. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Pre-existing Autoimmune Disorders. J Clin Oncol Off J Am Soc Clin Oncol 2018 Jul;36(19):1905-12.
  19. Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G, et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Vol. 27, Annals of oncology: official journal of the European Society for Medical Oncology. England; 2016. p. 1174-7.
  20. Richter MD, Pinkston O, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Brief Report: Cancer Immunotherapy in Patients With Pre-existing Rheumatic Disease: The Mayo Clinic Experience. Arthritis Rheumatol (Hoboken, NJ) 2018 Mar;70(3):356-60.
  21. Danlos F-X, Voisin A-L, Dyevre V, Michot J-M, Routier E, Taillade L, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 2018 Mar;91:21-9.
  22. Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and pre-existing autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017;75:24-32.
  23. Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, et al. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. Eur J Cancer 2018 Mar;105:88-102.
  24. Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer 2017;82:34-44.
  25. Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, et al. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Eur Urol 2019 Jul;76(1):73-81.
  26. Kaur A, Doberstein T, Amberker RR, Garje R, Field EH, Singh N. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience. Medicine (Baltimore) 2019 Oct;98(41):e17348.
  27. Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C. Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica. Drugs Aging 2019 Nov;36(11):1015-26.
  28. Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity. RMD Open 2017;3(1).
  29. Kähler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother 2018 May;67(5):825-34.
  30. Martinez Chanza N, Xie W, Issa M, Dzimitrowicz H, Tripathi A, Beuselinck B, et al. Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. J Immunother Cancer 2020 Mar;8(1).
  31. Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y. Pembrolizumab Therapy Triggering an Exacerbation of Pre-existing Autoimmune Disease: A Report of 2 Patient Cases. J Investig Med High Impact Case Reports 2016;4(4):2324709616674316.
  32. Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 2013 Sep;15(5):R136.
  33. Barbacki A, Maliha PG, Hudson M, Small D. A case of severe Pembrolizumab-induced neutropenia. Anticancer Drugs 2018 Sep;29(8):817-9.
  34. Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single‐Center Cohort of Sixty‐One Patients. Arthritis Rheumatol 2019 Mar;71(3):468-75.
  35. Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother 2019 Jun;68(6):917-26.
  36. Maul L V., Weichenthal M, Kähler KC, Hauschild A. Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease. J Immunother 2016;39(4):188-90.
  37. Yamada T, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, et al. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Pre-existing Granulomatosis with Polyangiitis. Intern Med 2019 Nov;58(21):3129-32.
  38. Nabel CS, Severgnini M, Hung YP, Cunningham‐Bussel A, Gjini E, Kleinsteuber K, et al. Anti‐PD‐1 Immunotherapy‐Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. Oncologist 2019;24(8):1013-21.
  39. Tun Min S, Nordman IIC, Tran HA. Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma. Case Rep Oncol 2019;12(2):639-43.
  40. Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, et al. Safety and efficacy of PD-1/PD-L1 blockade in patients with pre-existing antinuclear antibodies. Clin Transl Oncol [Internet] https://doi.org/10.1007/s12094-019-02214-82019;1(Mm)
  41. Tagliamento M, Grossi F, Paolino S, Rijavec E, Genova C, Rossi G, et al. Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy 2019 Jul;11(10):873-9.
  42. Jono M, Kinehara Y, Utsu Y, Tamura Y, Koseto M, Murakami T, et al. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus. Intern Med 2020 Feb;59(4):569-72.
  43. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, Varsamidakis N, Machairas A, Mandrekas D. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res 2000;20(6B):4351-3.
  44. Blaes F, Klotz M, Huwer H, Straub U, Kalweit G, Schimrigk K, et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 2000 Jan;69(1):254-8.
  45. Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, et al. Profiling Pre-existing Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2019 Mar;5(3):376-83.
  46. Yoneshima Y, Tanaka K, Shiraishi Y, Hata K, Watanabe H, Harada T, et al. Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. Lung Cancer 2019 Apr;130:5-9.
  47. Le Burel S, Champiat S, Mateus C, Marabelle A, Michot J-M, Robert C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer 2017 Sep;82:34-44.
  48. Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 2019 May;569(7756):428-32.
  49. Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 2018 Feb;128(2):715-20.